Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.

Abstract

OBJECTIVES The aim of this trial was to compare the safety and efficacy of paclitaxel-eluting stents (PES) and sirolimus-eluting stents (SES) for treatment of unprotected left main coronary artery (uLMCA) disease. BACKGROUND Both PES and SES have reduced the risk of restenosis, particularly in high-risk patient and lesion subsets. However, their… (More)
DOI: 10.1016/j.jacc.2009.01.035

Topics

6 Figures and Tables

Slides referencing similar topics